期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 5, 页码 2382-2418出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c01180
关键词
-
资金
- Elsevier Language Editing Services [331566771]
- National Science and Technology Major Project of the Ministry of Science and Technology of China [2018ZX09735005]
- National Natural Science Foundation of China [81922064, 81673455, 81803365, 81873939]
- Post-Doctor Research Project [2018M643510]
TNBC, the most aggressive subtype of breast cancer, lacks effective targeted therapy. Novel small-molecule drugs targeting specific molecular characteristics of TNBC may be a promising intervention, but face challenges. Emerging strategies such as dual-target drugs, drug repurposing, and combination strategies offer new insights for improving TNBC therapeutics.
Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, but an effective targeted therapy has not been wellestablished so far. Considering the lack of effective targets, where do we go next in the current TNBC drug development? A promising intervention for TNBC might lie in de novo small-molecule drugs that precisely target different molecular characteristics of TNBC. However, an ideal single-target drug discovery still faces a huge challenge. Alternatively, other new emerging strategies, such as dual-target drug, drug repurposing, and combination strategies, may provide new insight into the improvement of TNBC therapeutics. In this review, we focus on summarizing the current situation of a series of candidate small-molecule drugs in TNBC therapy, including single-target drugs, dual-target drugs, as well as drug repurposing and combination strategies that will together shed new light on the future directions targeting TNBC vulnerabilities with small-molecule drugs for future therapeutic purposes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据